Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autogene cevumeran - Genentech

Next Previous
Drug Profile

Autogene cevumeran - Genentech

Alternative Names: BNT-122; BNT122/RO7198457; Individualized Neoantigen Specific immunotherapy; iNeST; IVAC_M_uID; PCV RO7198457; Personalized cancer vaccine RO7198457; RG-6180; RG6180-1; RO-7198457

Latest Information Update: 21 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioNTech
  • Developer BioNTech; Genentech; Memorial Sloan-Kettering Cancer Center; Roche
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Adenocarcinoma; Colorectal cancer; Malignant melanoma; Urogenital cancer
  • No development reported Pancreatic cancer; Solid tumours; Triple negative breast cancer

Most Recent Events

  • 01 Jul 2025 Genentech completes the phase I trial in Solid tumours (Monotherapy, Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium, Canada, Germany, Netherlands, Spain, Sweden, United Kingdom, USA(IV) (EudraCT2017-001475-23) (NCT03289962)
  • 01 Jul 2025 Roche suspends phase IMCODE004 II trial in Urogenital cancer (Combination therapy, Adjuvant therapy) in Australia, USA, Argentina, Belgium, Canada, Denmark, France, Germany, Greece, Italy, South Korea, Mexico, Netherlands, Norway, Poland, Spain, Sweden, Taiwan and United Kingdom (IV), due to safety event observed in safety run-in population (NCT06534983)
  • 28 May 2025 No recent reports of development identified for phase-I development in Pancreatic-cancer(Combination therapy, First-line therapy) in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top